Alzheimer's Disease Screening in Annual Wellness Visit
GIA® delivers cognitive, depression, and anxiety screening at the annual wellness visit in 40 seconds via tablet or video — completing the AWV cognitive requirement and CPT 96127 behavioral screening in a single interaction, without consuming clinician face time. Results write back to the EHR for clinician review under 2 minutes.
Alzheimer’s disease and related dementias affect an estimated 6.9 million Americans age 65 and older as of 2024 — about 1 in 9 (10.9%) of US adults in that age group (Alzheimer’s Association, 2024 Facts and Figures). Clinical recognition of dementia in primary care has a sensitivity of 73.4% by clinician judgment, but recognition is documented in medical records only 37.9% of the time (Mitchell, Meader, Pentzek, Acta Psychiatrica Scandinavica 2011; meta-analysis of 15 dementia studies). Contemporary US Medicare data surface a different problem: dementia is diagnosed slightly more frequently than expected in aggregate (observed/expected ratio 1.086–1.104, 2015–2019) but substantially under-diagnosed in non-Hispanic Black (0.696) and Hispanic (0.758) beneficiaries compared with non-Hispanic White (1.367) (Mattke et al., Alzheimer’s Research & Therapy 2023; PMCID PMC10362635). Missed and delayed Alzheimer’s diagnosis is associated with higher rates of hospitalization, longer hospital stays, increased emergency department visits, and inappropriate medication management. Peer-reviewed speech biomarker research underlying GIA® reports AUC 0.890 for cognitive decline detection — the trajectory that includes mild cognitive impairment, Alzheimer’s disease, and related dementias. 42 CFR § 410.15(a)(v) lists detection of any cognitive impairment as a required element of the Medicare annual wellness visit.
The Medicare annual wellness visit requires detection of any cognitive impairment that the individual may have as a core element of the personalized prevention plan, under 42 CFR § 410.15. CMS does not mandate a specific instrument — clinicians are explicitly directed to “consider using brief cognitive tests.” GIA® delivers a 40-second speech-biomarker screening that fits inside the existing annual wellness visit workflow, capturing the cognitive-detection element plus depression and anxiety screening in a single patient interaction.
Why Alzheimer's Disease goes undetected in annual wellness visit
The annual wellness visit is delivered by a primary-care physician, nurse practitioner, or physician assistant in a 25–45 minute encounter. Medical assistants gather vitals and history. The cognitive screening component competes with every other AWV element for visit time. Alzheimer's Disease symptoms are often subtle, progressive, and easily attributed to other factors in this care environment.
CMS requires cognitive screening at every annual wellness visit but does not specify a tool — many practices skip the component or use unstandardized methods that may not survive survey
Annual wellness visit completion rates across primary care average well below the eligible Medicare population — most of the gap is time constraints, not patient unwillingness
The cognitive screening component, when positive, opens reimbursement for CPT 99483 (Cognitive Care Plan visit) — but only when documentation supports it
Depression and anxiety screening at the annual wellness visit are reimbursable under CPT 96127 (brief emotional/behavioral assessment, scored standardized instrument) — captured per administration
MIPS Promoting Interoperability category measures reward consistent screening-workflow integration across the practice's AWV population
How does GIA® screen for Alzheimer's Disease in annual wellness visit?
GIA® meets the patient by video, voice, or landline — wherever they are in the annual wellness visit environment. The screening conversation takes 40 seconds and feels like a natural check-in, not a clinical assessment.
During the conversation, GIA® analyzes over 2,500 speech biomarkers — including vocal tremor, articulatory precision, prosodic patterns, and cognitive load indicators — alongside 436 visual data points from facial micro-expressions and body movement during video sessions.
Results are delivered to the clinician in under 2 minutes. Four data types write back to the EHR automatically: structured screening results with ICD-10 codes, clinician-ready medical notes, a full timestamped transcript, and the recorded patient video. The clinician reviews and submits — the human is always in the loop.
Alzheimer's Disease in annual wellness visit: the numbers.
The screening challenge
The cognitive-detection element of the annual wellness visit competes for clinician face time against every other AWV requirement — health risk assessment, medical and family history, vitals, depression and substance-use screening, functional ability, fall risk, advance care planning. In a 25–45 minute encounter, most practices either skip the cognitive element, complete it with unstandardized direct observation, or document it pro forma. GIA® delivers the cognitive-detection element as structured, reviewable evidence without consuming clinician visit time. Documentation supports billing accuracy for G0438 / G0439; coding decisions remain with the clinical documentation and coding team.
What compliance requirements does this address?
G0438 (initial annual wellness visit) and G0439 (subsequent annual wellness visit) require documented cognitive screening as a core element. CPT 99483 (Cognitive Care Plan visit, 60 minutes) is separately reimbursable when a clinician documents cognitive impairment. CPT 96127 (brief emotional/behavioral assessment, scored standardized instrument) applies per administration to depression and anxiety screening, which GIA® supports alongside cognitive screening in the same 40-second interaction. Documentation supports billing accuracy; coding decisions remain with the clinical documentation and coding team.
GIA® produces structured documentation automatically — screening results with ICD-10 codes, clinician-ready medical notes, full timestamped transcripts, and recorded patient video — all written back to the EHR in real time and available for clinical, billing, and compliance review.
Alzheimer's Disease screening in annual wellness visit
How is Alzheimer's Disease screened in annual wellness visit?
GIA® screens for Alzheimer's Disease through a single conversational interaction lasting 40 seconds. She analyzes over 2,500 speech biomarkers using Voice AI, Computer Vision, and Speech Biomarkers. GIA® delivers cognitive, depression, and anxiety screening at the annual wellness visit in 40 seconds via tablet or video — completing the AWV cognitive requirement and CPT 96127 behavioral screening in a single interaction, without consuming clinician face time. Results write back to the EHR for clinician review under 2 minutes. Results are delivered to the clinician in under 2 minutes.
Does Alzheimer's Disease screening require additional staff?
No. GIA® conducts the screening conversation independently — zero additional clinical staff required during the interaction. The annual wellness visit is delivered by a primary-care physician, nurse practitioner, or physician assistant in a 25–45 minute encounter. Medical assistants gather vitals and history. The cognitive screening component competes with every other AWV element for visit time. The clinician reviews the results in under 2 minutes.
What is the accuracy of Alzheimer's Disease screening?
Alzheimer's Disease screening accuracy: Clinically validated vocal biomarker screening. The platform is peer-reviewed across 19 published studies and trained on 12.3 million longitudinal PAC/LTC patient records and 27 billion clinical events.
What does 42 CFR § 410.15 require for cognitive impairment detection at the annual wellness visit?
The regulation lists detection of any cognitive impairment as a required element of both the first and subsequent annual wellness visits. “Detection” is defined as assessment of an individual’s cognitive function by direct observation, with due consideration of information obtained by way of patient report or concerns raised by family, friends, or caretakers. CMS does not mandate a specific instrument — clinicians choose the method, and CMS guidance states “consider using brief cognitive tests.”
Which HCPCS codes apply to the annual wellness visit?
G0438 covers the initial annual wellness visit (one per beneficiary lifetime, no earlier than 12 months after Medicare Part B enrollment). G0439 covers subsequent annual wellness visits (one per 12-month period thereafter). Both require a documented personalized prevention plan that includes cognitive impairment detection.
How does GIA® support documentation for G0438 and G0439?
GIA® writes structured screening results, ICD-10 codes, clinician-ready medical notes, a full timestamped transcript, and the recorded patient video back to the EHR in real time. That documentation supports billing accuracy for the cognitive-detection element of G0438 or G0439. Coding decisions remain with the clinical documentation and coding team, and reimbursement determinations are made by the payer based on the complete documented encounter.
When during the annual wellness visit does GIA® screen the patient?
GIA® screens during rooming or in the waiting area before the clinician enters. The 40-second conversation produces results in under two minutes — typically before the clinician begins the face-to-face portion. The clinician reviews structured results during the visit instead of administering a separate cognitive instrument.
How does GIA® screen for Alzheimer’s disease?
GIA® analyzes 2,500+ speech biomarkers — including word-finding latency, semantic coherence, processing speed, articulation, and prosodic markers associated with cognitive change — during a natural conversation lasting 40 seconds. Peer-reviewed biomarker accuracy for cognitive decline detection (the trajectory that includes mild cognitive impairment, Alzheimer’s disease, and related dementias) is AUC 0.890. Results write back to the EHR with structured notes for clinician review. A clinician reviews and approves every result before it enters the clinical record.
Why is Alzheimer’s underdetected and underdocumented in primary care?
A 2011 meta-analysis of 15 dementia studies (Mitchell, Meader, Pentzek, Acta Psychiatrica Scandinavica) found GPs recognized 73.4% of dementia cases by clinical judgment but documented the recognition in medical records only 37.9% of the time. Contemporary US Medicare data (Mattke et al., Alzheimer’s Research & Therapy 2023) show dementia is over-diagnosed in aggregate but substantially under-diagnosed in non-Hispanic Black (detection ratio 0.696) and Hispanic (0.758) beneficiaries versus non-Hispanic White (1.367). Non-memory presentations of early Alzheimer’s — executive dysfunction, behavioral change, sleep disturbance — are commonly cited contributors to missed detection.
How does GIA® support cognitive-impairment detection at the annual wellness visit?
42 CFR § 410.15(a)(v) lists detection of any cognitive impairment as a required element of both the initial and subsequent Medicare annual wellness visits. GIA® delivers a structured speech-biomarker-based screen in 40 seconds — operationally compatible with the AWV visit envelope — and writes results back to the EHR for clinician review. The same 40-second screening also supports depression risk-factor review under § 410.15(a)(vi). Documentation supports billing accuracy; coding decisions remain with the clinical documentation and coding team.
Does GIA® diagnose Alzheimer’s disease?
No. GIA® screens — she does not diagnose. She surfaces structured risk signals from speech biomarker analysis for clinician review. The clinician applies clinical judgment, reviews additional data (cognitive history, neuropsychological testing, neuroimaging, biomarkers, family history, functional assessment), and makes any diagnostic determination, including the differential between Alzheimer’s disease and other dementia etiologies. GIA® is a clinical decision support tool with mandatory clinician-in-the-loop review on every result.
What is the limitation of standard Alzheimer’s screening tools in primary care?
The MMSE, MoCA, SLUMS, and Mini-Cog all require trained clinician administration and 5 to 30 minutes per patient. The MMSE has well-documented ceiling effects in early disease and weak coverage of executive function. The MoCA is more sensitive but requires more clinician time. Sensory deficits, language differences, and patient fatigue further compromise reliability. None of these instruments is well-suited to detecting the non-memory-dominant presentations of early Alzheimer’s. GIA® analyzes speech biomarkers across multiple cognitive domains from natural conversation without requiring clinician administration time or instrument-specific selection.
Alzheimer's Disease screening in other care settings
Other conditions screened in annual wellness visit
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.
See GIA® screen for Alzheimer's Disease live
40 seconds. 60-second results. Zero staff time.